RxDoctor Payments Data

Malcolm McHarg, MD

Neurology with Special Qualifications in Child Neurology · Blue Bell, PANPI 1689614042

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 34.2% of the total. Reporting peaked in 2024 at $223 and has fallen 69.8% since, to $67 in 2025. That places this record below the midpoint for neurology with special qualifications in child neurology clinicians in PA, where the typical reported total is $761.

$732in general payments, 2019–2025

Across 52 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$250
  • Ironshore Pharmaceuticals Inc.$158
  • Novartis$104
  • Collegium Pharmaceutical, Inc.$67
  • Tris Pharma Inc$34
  • Pfizer$24
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$732 in reported general payments places this provider in the 45th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.

See all neurology with special qualifications in child neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$62,477
Medicare patients
299
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lacosamide73$9,159
Levetiracetam157$6,387
Memantine Hcl52$3,450
DilantinPhenytoin Sodium Extended31$2,378
Lamotrigine79$2,226
Methylphenidate ErMethylphenidate Hcl11$2,156
Phenobarbital25$1,759
Donepezil Hcl86$1,245
Pyridostigmine Bromide13$1,236
Divalproex Sodium28$1,171
Gabapentin44$1,128
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,086
Phenytoin Sodium Extended43$993
Primidone30$683
Zonisamide20$624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerDilantin$24$2,37831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.

Other neurology with special qualifications in child neurology in Blue Bell

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →